ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL729
CHEMBL729
Compound Name LOPINAVIR
ChEMBL Synonyms A-157378.0 | Kaletra | A-157378-0 | ABT-378 | LOPINAVIR
Max Phase 4 (Approved)
Trade Names Kaletra
Molecular Formula C37H48N4O5

Additional synonyms for CHEMBL729 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc2ccccc2)N ...
Download SMILES
Standard InChI InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44 ...
Download InChI
Standard InChI Key KJHKTHWMRKYKJE-SUGCFTRWSA-N

Sources

  • Drugs for Neglected Diseases Initiative (DNDi)
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


CHEMBL729

Molecule Features

CHEMBL729 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Human immunodeficiency virus type 1 protease inhibitor Human immunodeficiency virus type 1 protease FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
InfectionD007239EFO:0000544infection2ClinicalTrials
Hepatitis CD006526EFO:0003047hepatitis C infection1ClinicalTrials
Sarcoma, KaposiD012514EFO:0000558Kaposi's sarcoma2ClinicalTrials
TuberculosisD014376Orphanet:3389Tuberculosis1ClinicalTrials
Insulin ResistanceD007333EFO:0002614insulin resistance1ClinicalTrials
Acquired Immunodeficiency SyndromeD000163EFO:0000765AIDS3ClinicalTrials
HIV InfectionsD015658EFO:0000180HIV-1 infection3ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection3ClinicalTrials

Clinical Data

ClinicalTrials.gov LOPINAVIR
The Cochrane Collaboration LOPINAVIR

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
628.8 628.3625 4.33 15 120 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 4 1 9 4 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.89 - 5.42 5.42 3 46 0.2

Structural Alerts

There are 1 structural alerts for CHEMBL729. To view alerts please click here.

Compound Cross References

ChemSpider ChemSpider:KJHKTHWMRKYKJE-SUGCFTRWSA-N
DailyMed lopinavir
PubChem SID: 124893167 SID: 144205757 SID: 170464773 SID: 26757998 SID: 50111692
Wikipedia Lopinavir

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL729



ACToR 192725-17-0
BindingDB 578 50180655
Brenda 1430
ChEBI 31781
DrugBank DB01601
DrugCentral 1601
eMolecules 6719306
EPA CompTox Dashboard DTXSID8046456
FDA SRS 2494G1JF75
Human Metabolome Database HMDB0015539
IBM Patent System ED4FA681225524D56C29F8E1BFE6C8B0
KEGG Ligand C12871
LINCS LSM-6027
MolPort MolPort-003-848-410
Nikkaji J1.543.461I
PDBe AB1
PharmGKB PA450264
PubChem 92727
PubChem: Drugs of the Future 56310583
PubChem: Thomson Pharma 14912304 14912305
Selleck Lopinavir
SureChEMBL SCHEMBL21775
ZINC ZINC000003951740

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/KJHKTHWMRKYKJE-SUGCFTRWSA-N spacer
spacer